LFST Stock Analysis: Lifestance Health | NASDAQ
Medical Care Facilities | NASDAQ, USA | Market Cap: 4.303m USD | 12M Return: 126.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 37.5M
Qual. Beats: 0
Rev. Trend: 99.6%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
LifeStance Health Group, Inc. (NASDAQ: LFST) is a US-based provider of outpatient mental health services, treating children, adolescents, adults, and geriatric patients. Founded in 2017 and headquartered in Scottsdale, Arizona, the company completed its IPO in June 2021.
The company offers a multidisciplinary suite of clinical services, including psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family, and group therapy. Its clinicians address conditions such as anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and PTSD.
Care is delivered through a hybrid model that combines a network of physical outpatient centers with a virtual online platform, supporting both in-person and telehealth visits. Like other large US behavioral health operators, the companys business model is built on a clinician-centric, multi-state center footprint paired with virtual care to broaden patient access.
- Patient visit volume growth drives double-digit revenue gains
- Clinician recruiting costs pressure operating margins
- Payor mix shift toward commercial plans supports reimbursement rates
| Net Income: 23.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 3.47 > 1.0 |
| NWC/Revenue: 7.77% < 20% (prev 7.58%; Δ 0.20% < -1%) |
| CFO/TA 0.08 > 3% & CFO 182.4m > Net Income 23.2m |
| Net Debt (311.2m) to EBITDA (98.3m): 3.17 < 3 |
| Current Ratio: 1.48 > 1.5 & < 3 |
| Outstanding Shares: last quarter (395.1m) vs 12m ago 1.13% < -2% |
| Gross Margin: 32.60% > 18% (prev 32.53%; Δ 0.07% > 0.5%) |
| Asset Turnover: 70.33% > 50% (prev 60.98%; Δ 9.35% > 0%) |
| Interest Coverage Ratio: 4.24 > 6 (EBIT TTM 44.0m / Interest Expense TTM 10.4m) |
| A: 0.05 (Total Current Assets 355.9m - Total Current Liabilities 239.7m) / Total Assets 2.15b |
| B: -0.37 (Retained Earnings -794.4m / Total Assets 2.15b) |
| C: 0.02 (EBIT TTM 44.0m / Avg Total Assets 2.13b) |
| D: 2.21 (Book Value of Equity 1.48b / Total Liabilities 668.5m) |
| Altman-Z'' = 1.61 = BB |
| DSRI: 0.75 (Receivables 122.9m/140.4m, Revenue 1.49b/1.28b) |
| GMI: 1.00 (GM 32.53% / 32.60%) |
| AQI: 0.97 (AQ_t 0.69 / AQ_t-1 0.71) |
| SGI: 1.16 (Revenue 1.49b / 1.28b) |
| TATA: -0.07 (NI 23.2m - CFO 182.4m) / TA 2.15b) |
| Beneish M = -3.14 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 10.71 with a total of 2,851,990 shares traded. Over the past week, the price has changed by -5.01%, over one month by +36.20%, over three months by +67.27% and over the past year by +126.32%.
Current recommended Stop Loss: 10.20 (which is 4.8% or 1.2 ATR below the current price).
Lifestance Health has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy LFST.
- StrongBuy: 5
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 10.6 | -1.5% |
P/E Trailing = 187.8333
P/E Forward = 75.188
P/S = 2.8788
P/B = 2.9127
Revenue TTM = 1.49b USD
EBIT TTM = 44.0m USD
EBITDA TTM = 98.3m USD
Long Term Debt = 262.5m USD (from longTermDebt, last quarter)
Short Term Debt = 47.4m USD (from shortTermDebt, last quarter)
Debt = 506.0m USD (corrected: LT Debt 262.5m + ST Debt 47.4m) + Leases 196.2m
Net Debt = 311.2m USD (calculated: Debt 506.0m - CCE 194.8m)
Enterprise Value = 4.61b USD (4.30b + Debt 506.0m - CCE 194.8m)
Interest Coverage Ratio = 4.24 (Ebit TTM 44.0m / Interest Expense TTM 10.4m)
EV/FCF = 25.81x (Enterprise Value 4.61b / FCF TTM 178.8m)
FCF Yield = 3.87% (FCF TTM 178.8m / Enterprise Value 4.61b)
FCF Margin = 11.96% (FCF TTM 178.8m / Revenue TTM 1.49b)
Net Margin = 1.55% (Net Income TTM 23.2m / Revenue TTM 1.49b)
Gross Margin = 32.60% ((Revenue TTM 1.49b - Cost of Revenue TTM 1.01b) / Revenue TTM)
Gross Margin QoQ = 33.69% (prev 33.04%)
Tobins Q-Ratio = 2.15 (Enterprise Value 4.61b / Total Assets 2.15b)
Interest Expense / Debt = 2.05% (Interest Expense 10.4m / Debt 506.0m)
Taxrate = 30.95% (10.4m / 33.6m)
NOPAT = 30.4m (EBIT 44.0m * (1 - 30.95%))
Current Ratio = 1.48 (Total Current Assets 355.9m / Total Current Liabilities 239.7m)
Debt / Equity = 0.34 (Debt 506.0m / totalStockholderEquity, last quarter 1.48b)
Debt / EBITDA = 3.17 (Net Debt 311.2m / EBITDA 98.3m)
Debt / FCF = 1.74 (Net Debt 311.2m / FCF TTM 178.8m)
Total Stockholder Equity = 1.49b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.09% (Net Income 23.2m / Total Assets 2.15b)
RoE = 1.56% (Net Income TTM 23.2m / Total Stockholder Equity 1.49b)
RoCE = 2.51% (EBIT 44.0m / Capital Employed (Equity 1.49b + L.T.Debt 262.5m))
RoIC = 1.62% (NOPAT 30.4m / Invested Capital 1.88b)
WACC = 8.07% (E(4.30b)/V(4.81b) * Re(8.85%) + D(506.0m)/V(4.81b) * Rd(2.05%) * (1-Tc(0.31)))
Discount Rate = 8.85% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.67 | Cagr: 2.72%
[DCF] Terminal Value 77.97% ; FCFF base≈148.2m ; Y1≈169.9m ; Y5≈250.0m
[DCF] Fair Price = 9.04 (EV 3.76b - Net Debt 311.2m = Equity 3.45b / Shares 381.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.29 | # QB: 0
Revenue Correlation: 99.64 | Revenue CAGR: 16.74% | SUE: 3.69 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.08 | Chg30d=N/A | Revisions=+57% | Analysts=5
EPS next Quarter (2026-09-30): EPS=0.07 | Chg30d=N/A | Revisions=+0% | Analysts=5
EPS current Year (2026-12-31): EPS=0.31 | Chg30d=N/A | Revisions=+17% | GrowthEPS=+70.8% | GrowthRev=+16.8%
EPS next Year (2027-12-31): EPS=0.39 | Chg30d=N/A | Revisions=+29% | GrowthEPS=+25.9% | GrowthRev=+13.9%
[Analyst] Revisions Ratio: +39% (up=11, down=4)